1,479
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A novel microdeletion syndrome at 3q13.31 characterised by developmental delay, postnatal overgrowth, hypoplastic male genitals, and characteristic facial features

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Congenital deletions affecting 3q11q23 have rarely been reported and only five cases have been molecularly characterised. Genotype—phenotype correlation has been hampered by the variable sizes and breakpoints of the deletions. In this study, 14 novel patients with deletions in 3q11q23 were investigated and compared with 13 previously reported patients.

          Methods

          Clinical data were collected from 14 novel patients that had been investigated by high resolution microarray techniques. Molecular investigation and updated clinical information of one cytogenetically previously reported patient were also included.

          Results

          The molecular investigation identified deletions in the region 3q12.3q21.3 with different boundaries and variable sizes. The smallest studied deletion was 580 kb, located in 3q13.31. Genotype—phenotype comparison in 24 patients sharing this shortest region of overlapping deletion revealed several common major characteristics including significant developmental delay, muscular hypotonia, a high arched palate, and recognisable facial features including a short philtrum and protruding lips. Abnormal genitalia were found in the majority of males, several having micropenis. Finally, a postnatal growth pattern above the mean was apparent. The 580 kb deleted region includes five RefSeq genes and two of them are strong candidate genes for the developmental delay: DRD3 and ZBTB20.

          Conclusion

          A newly recognised 3q13.31 microdeletion syndrome is delineated which is of diagnostic and prognostic value. Furthermore, two genes are suggested to be responsible for the main phenotype.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Dopamine receptors: from structure to function.

          The diverse physiological actions of dopamine are mediated by at least five distinct G protein-coupled receptor subtypes. Two D1-like receptor subtypes (D1 and D5) couple to the G protein Gs and activate adenylyl cyclase. The other receptor subtypes belong to the D2-like subfamily (D2, D3, and D4) and are prototypic of G protein-coupled receptors that inhibit adenylyl cyclase and activate K+ channels. The genes for the D1 and D5 receptors are intronless, but pseudogenes of the D5 exist. The D2 and D3 receptors vary in certain tissues and species as a result of alternative splicing, and the human D4 receptor gene exhibits extensive polymorphic variation. In the central nervous system, dopamine receptors are widely expressed because they are involved in the control of locomotion, cognition, emotion, and affect as well as neuroendocrine secretion. In the periphery, dopamine receptors are present more prominently in kidney, vasculature, and pituitary, where they affect mainly sodium homeostasis, vascular tone, and hormone secretion. Numerous genetic linkage analysis studies have failed so far to reveal unequivocal evidence for the involvement of one of these receptors in the etiology of various central nervous system disorders. However, targeted deletion of several of these dopamine receptor genes in mice should provide valuable information about their physiological functions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Molecular mechanisms, biological actions, and neuropharmacology of the growth-associated protein GAP-43.

            W B Denny (2006)
            GAP-43 is an intracellular growth-associated protein that appears to assist neuronal pathfinding and branching during development and regeneration, and may contribute to presynaptic membrane changes in the adult, leading to the phenomena of neurotransmitter release, endocytosis and synaptic vesicle recycling, long-term potentiation, spatial memory formation, and learning. GAP-43 becomes bound via palmitoylation and the presence of three basic residues to membranes of the early secretory pathway. It is then sorted onto vesicles at the late secretory pathway for fast axonal transport to the growth cone or presynaptic plasma membrane. The palmitate chains do not serve as permanent membrane anchors for GAP-43, because at steady-state most of the GAP-43 in a cell is membrane-bound but is not palmitoylated. Filopodial extension and branching take place when GAP-43 is phosphorylated at Ser-41 by protein kinase C, and this occurs following neurotrophin binding and the activation of numerous small GTPases. GAP-43 has been proposed to cluster the acidic phospholipid phosphatidylinositol 4,5-bisphosphate in plasma membrane rafts. Following GAP-43 phosphorylation, this phospholipid is released to promote local actin filament-membrane attachment. The phosphorylation also releases GAP-43 from calmodulin. The released GAP-43 may then act as a lateral stabilizer of actin filaments. N-terminal fragments of GAP-43, containing 10-20 amino acids, will activate heterotrimeric G proteins, direct GAP-43 to the membrane and lipid rafts, and cause the formation of filopodia, possibly by causing a change in membrane tension. This review will focus on new information regarding GAP-43, including its binding to membranes and its incorporation into lipid rafts, its mechanism of action, and how it affects and is affected by extracellular agents.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice.

              While most effects of dopamine in the brain are mediated by the D1 and D2 receptor subtypes, other members of this G protein-coupled receptor family have potentially important functions. D3 receptors belong to the D2-like subclass of dopamine receptors, activation of which inhibits adenylyl cyclase. Using targeted mutagenesis in mouse embryonic stem cells, we have generated mice lacking functional D3 receptors. A premature chain-termination mutation was introduced in the D3 receptor gene after residue Arg-148 in the second intracellular loop of the predicted protein sequence. Binding of the dopamine antagonist [125I]iodosulpride to D3 receptors was absent in mice homozygous for the mutation and greatly reduced in heterozygous mice. Behavioral analysis of mutant mice showed that this mutation is associated with hyperactivity in an exploratory test. Homozygous mice lacking D3 receptors display increased locomotor activity and rearing behavior. Mice heterozygous for the D3 receptor mutation show similar, albeit less pronounced, behavioral alterations. Our findings indicate that D3 receptors play an inhibitory role in the control of certain behaviors.
                Bookmark

                Author and article information

                Journal
                J Med Genet
                J. Med. Genet
                jmg
                jmedgenet
                Journal of Medical Genetics
                BMJ Group (BMA House, Tavistock Square, London, WC1H 9JR )
                0022-2593
                1468-6244
                17 December 2011
                February 2012
                17 December 2011
                : 49
                : 2
                : 104-109
                Affiliations
                [1 ]Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
                [2 ]Institut de Génétique Médicale, Hopital Jeanne de Flandre, CHRU de Lille, France
                [3 ]Department of Human Genetics, Institute for Genetic and Metabolic Disorders, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
                [4 ]Département de Génétique et INSERM U781, Université Paris Descartes, Hôpital, Necker-Enfants Malades, Paris, France
                [5 ]Medical Genetics Unit IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy
                [6 ]CHU Nantes, Service de genetique medicale, Nantes, France
                [7 ]Centre de Génétique Chromosomique, GHICL, Lille, France
                [8 ]Unità Operativa Malattie Metaboliche Genetica Medica, P.O. Giovanni XXIII, A.O.U. Policlinico Consorziale, Bari, Italy
                [9 ]Department of Clinical Genetics, Guy's & St Thomas' NHS Foundation Trust, London, UK
                [10 ]Department of Clinical Genetics, University Hospital, Rigshospitalet, Copenhagen, Denmark
                [11 ]Department of Neurology, Academic Hospital, University of São Paulo, Brazil
                [12 ]Department of Evolutionary Biology, Institute of Biosciences, University of São Paulo, Brazil
                [13 ]A.C. Camargo Hospital, São Paulo, Brazil
                [14 ]Inserm, UMR_S915, l'institut du thorax, Nantes, France
                [15 ]Department of Cytogenetics, Guy's & St Thomas' NHS Foundation Trust, London
                [16 ]Serviço de Genética Médica, Centro Hospitalar de Coimbra, Coimbra, Portugal
                [17 ]Service de Génétique Clinique, CHU d'Amiens, France
                [18 ]Our Lady's Hospital for Sick Children, Crumlin, Dublin 12, Ireland
                [19 ]Laboratoire de Cytogénétique, CHU d'Amiens, France
                [20 ]Rigshospitalet & Roskilde, Departments of Paediatrics, Denmark
                [21 ]Service de Neuropédiatrie, CHRU de Lille, France
                [22 ]Service de Génétique Médicale, Hôpital Jeanne de Flandre, CHRU de Lille, France
                Author notes
                Correspondence to Dr Anna-Maja Molin, Department of Animal Breeding and Genetics, Swedish University of Agricultural Sciences, Science for Life Laboratory, Uppsala 75237, Sweden; anna-maja.nystrom@ 123456slu.se
                Article
                jmedgenet-2011-100534
                10.1136/jmedgenet-2011-100534
                3261728
                22180640
                69243152-2ce7-4a8a-8ecc-b294467ec9eb
                © 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

                This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

                History
                : 28 September 2011
                : 10 November 2011
                : 16 November 2011
                Categories
                Copy-Number Variations
                1506
                Original article

                Genetics
                3q,developmental delay,overgrowth syndrome,microdeletion,genotype-phenotype
                Genetics
                3q, developmental delay, overgrowth syndrome, microdeletion, genotype-phenotype

                Comments

                Comment on this article